Adult T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic tumor associated with poor outcome. In this study, we analyzed the prognostic relevance of genetic alterations, immunophenotypic markers and microarray gene expression signatures in a panel of 53 adult T-ALL patients treated in the Eastern Cooperative Oncology Group (ECOG) E2993 clinical trial. An early immature gene expression signature, the absence of bi-allelic TCRG deletion, CD13 surface expression, heterozygous deletions of the short arm of chromosome 17, and mutations in IDH1/IDH2 and DNMT3A genes are associated with poor prognosis in this series. In contrast, expression of CD8 or CD62L, homozygous deletion of CDKN2A/CDKN2B, NOTCH1 and/or FBXW7 mutations, and mutations or deletions in the BCL11B tumor suppressor gene were associated with improved overall survival. Importantly, the prognostic relevance of CD13 expression and homozygous CDKN2A/CDKN2B deletions were restricted to cortical and mature T-ALLs. Conversely, mutations in IDH1/IDH2 and DNMT3A were specifically associated with poor outcome in early immature adult T-ALLs.
Introduction
T-cell acute lymphoblastic leukemias (T-ALL) account for 25% of adult ALL cases 1 completed with mutations in genes such as the ribosomal protein RPL10 5 and the dynamin DNM2 gene 6 whose functional role in T-cell transformation is yet to be fully understood.
Still, and despite this diversity of molecular and cytogenetic lesions, microarray gene expression studies have shown that T-ALLs can be classified in a limited number of transcriptional groups, which are related to the activation of specific transcription factor oncogenes and show distinct gene expression signatures related to their arrest at different stages of T-cell differentiation 1, [7] [8] [9] .
Thus, early immature T-ALLs, which are arrested early at the double negative stage of thymocyte development 1, 10, 11 , show a transcriptional program related to hematopoietic stem cells and myeloid progenitors 6, 11 , higher levels of LYL1 and LMO2 expression 1 and mutations in acute myeloid leukemia genes 6, 11 , together with inactivation of important transcription factors such as RUNX1, GATA3 and ETV6 6, 11 . Notably, these early immature tumors frequently show absence of biallelic TCRG deletions 12 and are associated with very poor prognosis 10, 12 . In contrast, CD1a positive T-ALLs show an early cortical gene expression signature, frequent activation of TLX1 and a favorable prognosis 1, 13 . Finally, leukemias with aberrant expression of TAL1 together with LMO1 and LMO2 are characterized by a gene expression program related to those of late cortical thymocytes 1 .
To gain insight on the clinical relevance of different genetic alterations and oncogenic pathways involved in T-cell transformation here analyzed the analysis of the prognostic significance of transcriptional, cytogenetic, immunophenotypic and molecular features of T-ALL leukemias treated in the Eastern Cooperative Oncology Group (ECOG) E2993 clinical trial 14 .
Methods

Patient samples
Bone marrow lymphoblast samples from 53 T-ALL patients treated in the E2993 Eastern
Cooperative Oncology Group clinical trial 14 (ClinicalTrials.gov identifier: NCT00002514) were 6 included in this study. All samples were collected with informed consent at trial entry according to the declaration of Helsinki and analyzed under the supervision of the Columbia University Medical Center Institutional Review Board.
Flow cytometry
Immunophenotypic analysis was performed at the ECOG leukemia reference laboratory as previously described 14 (Supplementary Table 1 ). Briefly, lymphoblasts were gated by 3-color flow cytometry based on antigen expression of the leukemic cells. In addition to cytoplasmic CD3 (cCD3) which established the diagnosis of T-ALL, T-lymphoid-affiliated antigens tested included CD1a, CD2, surface CD3, CD4, CD5, CD8, CD62L, CD57, and surface
The intensity of CD5 staining was determined as mean fluorescent intensity (mfi) as previously described 15 . Myeloid antigens included myeloperoxidase, CD117, CD33, CD13, CD65(s), CD15(s), CD11b, and CD14, and B-lymphoid-affiliated antigens included CD19 and CD10.
Finally, uncommitted antigens included CD45, CD34, HLA-DR, and TdT.
Microarray gene expression profiling of primary adult T-ALL samples
RNA was isolated using the RNeasy plus mini kit (Qiagen) according to manufacturer's protocol.
Next, 500 ng of RNA were amplified and biotinylated using the TotalPrep RNA Amplification Kit (Ambion) and hybridized to the HumanHT-12 v4 Expression BeadChip (Illumina). Gene expression profiling data were normalized using log2 transformation and quantile normalization.
Unsupervised consensus clustering was performed using the GenePattern application 16 .
Enrichment of the gene set associated with Early T-cell precursor (ETP) T-ALL was analyzed by GSEA using the t-test metric and 10,000 permutations of the genes. Microarray gene expression data is available in Gene Expression Omnibus (GEO accession code GSE42328).
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Microarray-based comparative genomic hybridization (array-CGH)
Array-CGH analysis was performed using the SurePrint G3 Human 1x1M oligonucleotide array platform (Agilent, Santa Clara, USA) according to manufacturer instructions (Agilent). Slides were scanned in a 2565AA DNA microarray scanner (Agilent). Microarray images were analyzed using feature extraction software (Agilent) and the data were subsequently imported into array-CGH analytics software (Agilent). 27 and PTEN 28 have been previously described.
Mutation analysis
Statistical analyses
Survival time was measured from the date of randomization to date of death for patients who died and to the date of the last follow-up for those who were alive at the time of the analysis. Multivariate survival analyses were performed with the Cox proportional-hazards model.
Covariates were selected using the least absolute shrinkage and selection operator (lasso) 29 
Results
Prognostic value of transcriptionally defined early immature and cortical-mature adult T-ALL groups
To analyze the prognostic relevance of molecular groups defined by gene expression profiling in adult T-ALL, we analyzed a series of 53 primary leukemia samples using gene expression oligonucleotide microarrays. As previously described 11 , unsupervised clustering analysis of microarray gene expression data in this series revealed the presence of 2 robust clusters of samples ( Figure 1A ). The first of these clusters encompassed 28 samples and corresponded to early immature leukemias ( Figure 1A , B), a group characterized by a gene expression signature related to that of hematopoietic stem cells and myeloid progenitors 11 . In contrast, the second of these clusters, referred here as cortical/mature leukemias, contained 28 samples ( Figure 1A cortical/mature 62% [95% CI: 40%-78%]; P = 0.0112; Figure 1C ).
Prognostic value of copy number alterations
Array CGH analysis in our adult T-ALL series revealed on average 6 copy number alterations ( Pediatric T-ALL patients with absence of bi-allelic TCRG deletion (ABD), a feature linked with developmental arrest at the earliest stages of thymocyte development, exhibit early induction failure and inferior overall survival rates 12 . Array CGH analysis of TCRG copy number in our series showed ABD of the TCRG locus in 27 out of 53 (51%) adult T-ALL samples. In addition, Figure 4D ) were associated with worse prognosis. Consistent with previous reports 11 , alterations in DNMT3A and IDH1/IDH2 were uniquely present in the early immature adult T-ALL group.
Prognostic value of cell surface markers
Immunophenotype analysis showed that our 53 adult T-ALL series encompasses 25 immature Figure 5C ) conferred better prognosis.
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Multivariate analysis
Next, multivariate Cox regression analysis revealed that CD13 and CD62L antigen expression, heterozygous 17p deletions and mutations in NOTCH1/FBXW7 and DNMT3A are independent prognostic markers in adult T-ALL treated on the E2993 protocol (Supplementary Table 5 ).
Risk stratification in early immature and cortical/mature adult T-cell leukemias
Given the broad gene expression, immunophenotypic and genetic differences between early immature and cortical/mature adult T-cell leukemias, we tested the significance of different prognostic markers in these two groups. This analysis revealed that the poor prognosis CD13
expression was restricted to the otherwise favorable clinical group of mature/cortical leukemias Figure 6D ). This is in contrast with IDH1/IDH2 mutations, which are also restricted to early immature adult T-ALLs, but only showed a trend towards worse clinical outcome (2 year survival: mutant 20% [95% CI: 8%-58%] vs. wild type 56% [95% CI: 34%-74%]; P = 0.12; Figure 6E ) in this group.
For Absence of a bi-allelic TCRG deletion, a molecular marker linked with a very early block in T-cell differentiation, has been associated with poor response to induction therapy and dismal 5-year event-free and overall survival in pediatric T-ALL patients treated on COG P9404 or DFCI 00-01 protocols 12 . More recently, the prognostic relevance of ABD was confirmed in pediatric T-ALL patients treated according to the Taiwan Pediatric Oncology Group (TPOG) protocols 34 and pediatric T-cell lymphoblastic lymphoma patients treated following a Berlin-Frankfurt-Munich (BFM)-ALL-type strategy 35 . In our patient series, ABD was identified in about half of adult T-ALL samples and found to confer poor overall survival. In addition, 22 out of 27 ABD adult T-ALL T-ALL is a cytogenetically stable disease with a limited number of chromosomal alterations per sample. Comparison of our aCGH analysis results with those of previously reported pediatric series showed major overlap and some differences. Among these, the frequency of MYB duplications (10/53; 19%) and RB1 deletions (9/53; 17%) in our adult patient series was higher than previously documented in pediatric studies 36, 37 . In addition, we failed to identify genomic deletions at the 6q14-6q22 locus which occur in 20-30% of pediatric T-ALLs 38 . Finally, the presence of multiple amplifications at 13q and 17q, and recurrent genomic deletions at 1p36 and 5q, suggest that these chromosomal regions could harbor novel T-ALL oncogenes and tumor suppressors, respectively.
Importantly, TP53 mutations have been previously associated with poor survival in pediatric T-ALL patients treated on the Pediatric Oncology Group protocol POG8862 39 . Moreover, TP53
deletions and mutations at relapse are associated with chemotherapy resistance, failure to achieve a second complete remission and poor survival 40 . In line with this notion, heterozygous deletions of the short arm of chromosome 17 encompassing the TP53 tumor suppressor gene predicted for worse clinical outcome in adult T-ALL. In contrast, homozygous deletions of the CDKN2A/CDKN2B locus on the short arm of chromosome 9 conferred better clinical outcome in our series. Consistently, loss of heterozygosity at the short arm of chromosome 9 has been associated with a favorable initial treatment response in pediatric T-ALL patients treated in the ALL-BFM-95 study protocol 41 .
Activation of NOTCH signaling through NOTCH1 and/or FBXW7 mutations has been associated with a favorable prognosis in several, but not all, pediatric study protocols [42] [43] [44] [45] and IDH2 conferred worse prognosis in adult T-ALL, and multivariate analysis pointed to DNMT3A mutations as independent prognostic factor. Importantly, these findings confirm the CD1E  CD1B  MAL  RGPD1  NOTCH3  RHOU  FAT1  RAPGEF5  CR2  LAT  CDC25B  MZB1  TCTEX1D2  SNTB2  CCDC138  SYNE2  ZNF154  MTA3  SEPT1  RNU6−15  MRPL14  PSMA6  CNPY4  SLC9A7  LATS2  NSFL1C  OGFRL1  PDXDC1  MANBA  TRAK1  TSPAN13  MFSD10  MGLL  PRKAG2  WDR45L  CTSA  ACTN4  C15orf39  LAPTM5  WDFY1  GNG7  FTH1  MN1  LYN  NFIL3  HHEX  PRSS57  FAM46A 
